- Collagen Solutions, the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has entered into a joint venture agreement with Cre8ive (CRE8IVE: China Resources & Investment Vehicle Limited). The Collagen Solutions Group provides collagen to a global customer base covering North America, Europe and Asia. In order to maximize the potential of our business and to open up the market in China, the Company has entered into an agreement to form a Joint Venture company, with offices and staff in Beijing.

Cre8ive is a conglomerate, operating solely within the People's Republic of China, focusing on exclusive or high barrier to entry investment opportunities. Collagen Solutions will provide the initial investment into the JV, in a controlled manner, whilst Cre8ive will provide the territory expertise, support services, administrative and regulatory support in Beijing. The initial holding of the joint venture company will be 60:40 in favour of Collagen Solutions.

At 8:33am: [LON:COS] COLLAGEN SOLUTIONS ORD 1P share price was 0p at 6.38p

Story provided by